Patents by Inventor Kimberly Vanover
Kimberly Vanover has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210322433Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.Type: ApplicationFiled: April 30, 2021Publication date: October 21, 2021Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
-
Patent number: 11124514Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.Type: GrantFiled: September 27, 2019Date of Patent: September 21, 2021Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
-
Patent number: 11053245Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.Type: GrantFiled: April 14, 2013Date of Patent: July 6, 2021Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon Mates, Robert Davis, Kimberly Vanover
-
Publication number: 20210186962Abstract: The present disclosure relates to the treatment of schizophrenia in adults, comprising the administration of pharmaceutical capsules comprising 42 mg of lumateperone (60 mg of lumateperone tosylate).Type: ApplicationFiled: December 18, 2020Publication date: June 24, 2021Inventors: Robert E. DAVIS, Kimberly VANOVER
-
Patent number: 11026951Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.Type: GrantFiled: July 10, 2019Date of Patent: June 8, 2021Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Kimberly Vanover, Peng Li, Sharon Mates, Robert Davis, Lawrence P. Wennogle
-
Publication number: 20210163481Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: ApplicationFiled: July 20, 2018Publication date: June 3, 2021Inventors: Peng LI, Hailin ZHENG, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
-
Publication number: 20210145829Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: ApplicationFiled: July 20, 2018Publication date: May 20, 2021Inventors: Peng LI, Wei YAO, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
-
Patent number: 10960009Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.Type: GrantFiled: April 23, 2019Date of Patent: March 30, 2021Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Kimberly Vanover, Peng Li, Sharon Mates, Robert Davis, Lawrence P. Wennogle
-
Patent number: 10960010Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.Type: GrantFiled: June 17, 2019Date of Patent: March 30, 2021Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Kimberly Vanover, Peng Li, Sharon Mates, Robert Davis, Lawrence P. Wennogle
-
Publication number: 20210060010Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: ApplicationFiled: September 9, 2020Publication date: March 4, 2021Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Wei YAO, Peng LI, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
-
Publication number: 20210000822Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.Type: ApplicationFiled: July 7, 2020Publication date: January 7, 2021Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER
-
Publication number: 20210002280Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.Type: ApplicationFiled: July 10, 2020Publication date: January 7, 2021Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER
-
Publication number: 20200407362Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.Type: ApplicationFiled: July 10, 2020Publication date: December 31, 2020Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER
-
Patent number: 10799500Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: GrantFiled: February 14, 2019Date of Patent: October 13, 2020Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Wei Yao, Peng Li, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
-
Publication number: 20200017499Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.Type: ApplicationFiled: September 27, 2019Publication date: January 16, 2020Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER, Lawrence WENNOGLE
-
Publication number: 20190328745Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.Type: ApplicationFiled: July 10, 2019Publication date: October 31, 2019Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
-
Publication number: 20190298730Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.Type: ApplicationFiled: June 17, 2019Publication date: October 3, 2019Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
-
Publication number: 20190290655Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.Type: ApplicationFiled: April 23, 2019Publication date: September 26, 2019Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
-
Patent number: 10322134Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.Type: GrantFiled: March 12, 2018Date of Patent: June 18, 2019Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Kimberly Vanover, Peng Li, Sharon Mates, Robert Davis, Lawrence P. Wennogle
-
Publication number: 20190175590Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: ApplicationFiled: February 14, 2019Publication date: June 13, 2019Inventors: Wei YAO, Peng LI, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
